CELL INTELLIGENCE · 肿瘤细胞治疗研究

以实体瘤特征为门控的超声预处理引导 CAR-T 治疗

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.

肿瘤相关 CD19⁺ 巨噬细胞诱导肝细胞癌免疫抑制微环境

Tumor-associated CD19(+) macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma.

IL-18 代谢重编程表达 CAR 的自然杀伤 T 细胞并增强其抗肿瘤活性

IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.

岩藻多糖-铜纳米颗粒增强肿瘤细胞铜死亡与肿瘤免疫微环境改善

Fucoidan-Copper Nanoparticles to Potentiate Cancer Cell Cuproptosis and Tumor Immune Microenvironment Enhancement.

anti-CD19 CAR-T（抗 CD19CAR-T 细胞）治疗肝细胞癌：I 期临床试验

Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

这是一项 I 期注册临床试验，评估抗 CD19CAR-T 细胞治疗肝细胞癌的安全性、可行性及初步疗效。当前状态：招募中。计划入组 12 例。试验地点：中国 · 杭州（共 2 个中心，其中中国 2 个）。登记号：NCT06676982。

iNKT 激动剂 ABX196 作为一种新型癌症免疫治疗增强剂在黑色素瘤和肝癌小鼠模型中的抗肿瘤活性展示

Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Mo

肝细胞癌过继性细胞治疗的现状及开发“现货型”疗法的挑战

Current Landscape of Adoptive Cell Therapy and Challenge to Develop "Off-The-Shelf" Therapy for Hepatocellular Carcinoma.

肝细胞癌不同分期外周单个核细胞表面标志物的评估：一项针对肝炎后肝硬化且 AFP 升高不显著患者早期准确诊断的试验

Peripheral Mononuclear Cells Surface Markers Evaluation in Different Stages of Hepatocellular Carcinoma; in a Trial for Early and Accurate Diagnosis i

AFP 升高不明显的肝细胞癌患者表现出淋巴细胞、NK 细胞及所有单核细胞亚群的显著减少。